CA2294018A1 - Methodes et compositions permettant d'inactiver des agents infectieux au moyen de lactoferrine et de molecules associees - Google Patents

Methodes et compositions permettant d'inactiver des agents infectieux au moyen de lactoferrine et de molecules associees Download PDF

Info

Publication number
CA2294018A1
CA2294018A1 CA002294018A CA2294018A CA2294018A1 CA 2294018 A1 CA2294018 A1 CA 2294018A1 CA 002294018 A CA002294018 A CA 002294018A CA 2294018 A CA2294018 A CA 2294018A CA 2294018 A1 CA2294018 A1 CA 2294018A1
Authority
CA
Canada
Prior art keywords
lactoferrin
infectious agent
fragment
pasteurized
naturally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002294018A
Other languages
English (en)
Inventor
Andrew G. Plaut
Jiazhou Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New England Medical Center Hospitals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2294018A1 publication Critical patent/CA2294018A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode permettant de réduire sensiblement le pouvoir pathogène d'un agent infectieux, sans aller jusqu'à le tuer, laquelle méthode consiste à éliminer ou dégrader une protéine de surface de l'agent infectieux, à mettre l'agent infectieux au contact de lactoferrine à l'état naturel, sensiblement pure, et non-pasteurisée dans des conditions suffisantes pour éliminer ou dégrader ladite protéine.
CA002294018A 1998-04-13 1999-04-12 Methodes et compositions permettant d'inactiver des agents infectieux au moyen de lactoferrine et de molecules associees Abandoned CA2294018A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8156498P 1998-04-13 1998-04-13
US60/081,564 1998-04-13
PCT/US1999/007931 WO1999052545A1 (fr) 1998-04-13 1999-04-12 Methodes et compositions permettant d'inactiver des agents infectieux au moyen de lactoferrine et de molecules associees

Publications (1)

Publication Number Publication Date
CA2294018A1 true CA2294018A1 (fr) 1999-10-21

Family

ID=22164962

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002294018A Abandoned CA2294018A1 (fr) 1998-04-13 1999-04-12 Methodes et compositions permettant d'inactiver des agents infectieux au moyen de lactoferrine et de molecules associees

Country Status (5)

Country Link
EP (1) EP0989860A4 (fr)
JP (1) JP2002508009A (fr)
AU (1) AU3554099A (fr)
CA (1) CA2294018A1 (fr)
WO (1) WO1999052545A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1635766A4 (fr) * 2003-06-06 2009-09-30 Agennix Inc Lactoferrine en tant qu'adjuvant de vaccins contre le cancer
GB0409748D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
ITRM20080163A1 (it) * 2008-03-26 2009-09-27 Maurizio Acri Uso della lattoferrina per la prevenzione delle sepsi neonatali in neonati prematuri
CN107586334B (zh) * 2017-08-29 2020-06-23 杭州医学院 一种治疗流感嗜血杆菌感染的血清的制备方法及该血清的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2673320B2 (ja) * 1990-01-25 1997-11-05 雪印乳業株式会社 う蝕原菌付着阻止剤
JP2818056B2 (ja) * 1990-09-07 1998-10-30 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
JP3100005B2 (ja) * 1992-07-28 2000-10-16 雪印乳業株式会社 ヒト免疫不全ウィルス感染・増殖抑制剤
JP3312946B2 (ja) * 1993-03-04 2002-08-12 雪印乳業株式会社 ウイルス感染・増殖抑制剤
ATE209862T1 (de) * 1994-02-16 2001-12-15 Pharming Intellectual Pty Bv Isolierung von lactoferrin aus milch
US5834424A (en) * 1995-07-12 1998-11-10 Gambit International Limited Use of lactoferrin for therapy of acute of chronic infectious diseases by the intracellular gram-positive pathogens streptococcus pyogenes and staphylococcus aureus
AU6641896A (en) * 1995-08-07 1997-03-05 New England Medical Center Hospitals, Inc., The Infant formula and infant formula additives

Also Published As

Publication number Publication date
WO1999052545A1 (fr) 1999-10-21
JP2002508009A (ja) 2002-03-12
EP0989860A4 (fr) 2000-07-19
EP0989860A1 (fr) 2000-04-05
AU3554099A (en) 1999-11-01

Similar Documents

Publication Publication Date Title
JP6100826B2 (ja) 黄色ブドウ球菌由来のポリペプチド及び使用方法
KR101951894B1 (ko) 미코박테리움 항원성 조성물
Leigh et al. Sortase anchored proteins of Streptococcus uberis play major roles in the pathogenesis of bovine mastitis in dairy cattle
Almagor et al. Inhibition of host cell catalase by Mycoplasma pneumoniae: a possible mechanism for cell injury
JPH0648956A (ja) ヒト免疫不全ウィルス感染・増殖抑制剤
Oliver et al. Virulence factors of Streptococcus uberis isolated from cows with mastitis
CA2388910C (fr) Activite antimicrobienne du premier groupe cationique de la lactoferrine humaine
JP2022513077A (ja) クロストリジウム・ディフィシル多成分ワクチン
AU2002344421A1 (en) Interleukin-18 inducing agent
CA2294018A1 (fr) Methodes et compositions permettant d'inactiver des agents infectieux au moyen de lactoferrine et de molecules associees
Confer et al. Pathogenesis and virulence of Pasteurella haemolytica in cattle: an analysis of current knowledge and future approaches
JP3072353B2 (ja) 胃炎，胃または十二指腸潰瘍予防食品
McCardell et al. Identification of a CHO cell-elongating factor produced by Vibrio cholerae O1
Arvidson et al. Neisseria gonorrhoeae mutants altered in toxicity to human fallopian tubes and molecular characterization of the genetic locus involved
US20020165128A1 (en) Compositions and methods for proteolytically inactivating infectious agents using lactoferrin and related molecules
CN114146171B (zh) 一种猪萎缩性鼻炎灭活疫苗及其制备方法
AU2015258239B2 (en) Polypeptides from staphylococcus aureus and methods of use
EP0420743A1 (fr) Vaccin protecteur contre l'hémophilose porcine
AU2012244060B2 (en) Polypeptides from staphylococcus aureus and methods of use
Maher Analysis of the Role of Bacillus oleronius Proteins in the Induction of Rosacea and Evaluation of Novel Therapeutics for the Treatment of Dermal and Ocular Rosacea
JP2002234849A (ja) 消化性潰瘍抑制組成物及びそれを含有する飲食品
Lamont et al. Recent Advances in Clostridium difficile and its Toxins: Report of a Workshop held at Tours, France, 4 May, 1995
Singh Mannheimia haemolytica-induced cytokine gene modulation in bovine leukocytes
JP2000136148A (ja) 細胞への付着阻害組成物
Rayner The interaction of bacteria with the respiratory mucosa in vitro and in vivo

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead